About 5.0% of Theseus Pharmaceuticals outstanding shares are owned by corporate
insiders. Insiders ownership of Theseus Pharmaceuticals refers to the amount of Theseus Pharmaceuticals equity owned by Theseus officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Theseus, including its current
ownership diagnostics.
The performance of Theseus Pharmaceuticals in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence Theseus Pharmaceuticals'
stock prices. When investing in Theseus Pharmaceuticals, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, Theseus Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as Theseus Pharmaceuticals carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.
How important is Theseus Pharmaceuticals's Liquidity
Theseus Pharmaceuticals
financial leverage refers to using borrowed capital as a funding source to finance Theseus Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Theseus Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Theseus Pharmaceuticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Theseus Pharmaceuticals' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Theseus Pharmaceuticals's total debt and its cash.
A Deeper Perspective
Theseus Pharmaceuticals shows a total of thirty-five million eight hundred sixty thousand
outstanding shares. Theseus Pharmaceuticals has 5.33 % if its
outstanding shares held by
insiders and 5.33 % owned by
institutional holders . Please note that no matter how much assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Ownership Breakdown
| Retail Investors94.67% | Insiders5.33% |
| Retail Investors | 94.67 |
| Insiders | 5.33 |
| Institutions | 0.0 |
Theseus Pharmaceuticals is getting insane
Current total risk alpha indicator falls down to -0.72. Possible price jump?
As of the 22nd of December, Theseus Pharmaceuticals has the
risk adjusted performance of
(0.037553), and Coefficient Of Variation of
(1,931). In relation to
fundamental indicators, the
technical analysis model makes it possible for you to check existing technical drivers of Theseus Pharmaceuticals, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate data for nineteen
technical drivers for Theseus Pharmaceuticals, which can be compared to its competition. Please validate
Theseus Pharmaceuticals semi deviation,
jensen alpha, as well as the
relationship between the Jensen Alpha and
semi variance to decide if Theseus Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 8.98 per share. Given that Theseus Pharmaceuticals has
jensen alpha of
(0.29), we advise you to double-check Theseus Pharmaceuticals's current market performance to make sure the company can sustain itself at a future point.
Our Final Take On Theseus Pharmaceuticals
While some other firms in the biotechnology industry are either recovering or due for a correction, Theseus may not be as strong as the others in terms of longer-term growth potentials. The inconsistency in the assessment between current Theseus valuation and our trade advice on Theseus Pharmaceuticals is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Theseus Pharmaceuticals.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Theseus Pharmaceuticals. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
